ESC 365 - Risk of bleeding in patients with and without cancer on antiplatelet therapy following myocardial infarction: a study in primary care

ESC Professional Premium Access

Risk of bleeding in patients with and without cancer on antiplatelet therapy following myocardial infarction: a study in primary care

Session: Anticoagulation in cancer

Topic: Cardio-Oncology

Speaker: Mr F. Van Den Berg (Groningen, NL)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Mr Freek Van Den Berg

University Medical Centre Groningen, Groningen (Netherlands (The))

0 follower

6 more presentations in this session

The impact of cancer on the risk of hospitalisation for bleeding among acute coronary syndrome patients: an analysis of the Virtual Cardio-Oncology Research Initiative (VICORI) database

Speaker: Doctor K. Ow (Leicester, GB)

Cardiovascular outcomes, mortality, and bleeding in patients with acute myocardial infarction and a history of cancer: a report from the multi-center, nationwide prospective database JAMIR

Speaker: Doctor A. Adachi (Sendai, JP)

Impact of cardiovascular events and major bleeding in mortality in patients with atrial fibrillation and active lung cancer: data from a multicentre, retrospective, observational study.

Speaker: Doctor A. Piserra (Malaga, ES)

Usefulness of low-dose direct oral anticoagulants for peripheral deep vein thrombosis of the lower extremities in cancer patients with cancer bleeding lesions

Speaker: Doctor A. Nonaka (Akashi, JP)

Age- and sex- specific rate of venous thromboembolism in cancer survivors: a nationwide cohort study

Speaker: Ms G. Sun (Copenhagen, DK)

Access the full session

Anticoagulation in cancer

Speakers: Mr F. Van Den Berg, Doctor K. Ow, Doctor A. Adachi, Doctor A. Piserra, Doctor A. Nonaka...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources